Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. (Nasdaq: ENSC) is a clinical-stage pharmaceutical company focused on developing abuse-deterrent drug formulations for opioids and stimulants, operating within the healthcare and life sciences sector. The company filed a Form 10-K annual report with the SEC on March 10, 2020, covering fiscal year 2019, providing a detailed look at its pipeline progress, risk factors, and financial position as it advanced its proprietary TAAP and MPAR abuse-deterrent platform technologies. Ensysce subsequently completed a SPAC merger to gain its public listing on Nasdaq. Investors and analysts tracking ENSC's regulatory milestones and clinical-stage developments can access the full filing history, SPAC transaction details, and real-time data by signing up at SpacDesk.